NEUROLOGY
Expert Insight View All

Intracranial atherosclerotic disease: Stroke mechanisms, management and recurrence

Intracranial atherosclerosis (ICAS) is a major cause of ischemic stroke worldwide. Recurrent ischemic events are most commonly associated with ICAS than with other stroke subtypes.1

30 Dec 2019
thumb

Professor Leung Wai-Hong Thomas

Head of Division of Neurology
(Academic Affairs),
Lee Quo Wei Professor of Neurology
Assistant Dean (Education),
Faculty of Medicine,
The Chinese University of Hong Kong

Meeting Highlight View All

Local real-world study interim analysis demonstrates promising results: TTFields therapy on quality-of-life for newly diagnosed glioblastoma patients

30 Jun 2021
thumb

Dr. Peter YM Woo

Specialist in Neurosurgery

Research Spotlight View All

Navigating anticoagulation strategies for preventing recurrent events in NVAF patients with ischemic stroke despite DOAC

The increasing incidence of ischemic stroke in patients receiving direct oral anticoagulants (DOACs) highlights the heightened risk of subsequent ischemic events.1 Yet, the effectiveness and safety of antithrombotic regimens following this condition remain uncertain.1 In this investigation, patient outcomes were compared between those receiving DOACs with or without an alternative antithrombotic regimen, and the risk factors for recurrent ischemic stroke while on anticoagulation were identified.1 The 6-year study period, spanning January 1, 2015 to December 31, 2020, included 45,946 non-valvular atrial fibrillation (NVAF) patients administered DOACs for stroke prevention.1 Among them, 2,908 patients experienced an ischemic stroke despite the DOAC treatment, and 2,337 NVAF patients were included in the final analysis.1 The findings demonstrated that switching to warfarin (aHR=1.96; 95% CI: 1.27-3.02; p=0.002) or another DOAC(aHR=1.62; 95% CI: 1.25-2.11; p<0.001) was associated with an elevated risk of recurrent ischemic stroke compared with maintaining the sameDOAC therapy.1 Furthermore, the addition of an antiplatelet agent did not exhibit a reduced risk of recurrent ischemic stroke.1 The risk factors of recurrent ischemic stroke include diabetes mellitus (DM), concurrent cytochrome P450/P-glycoprotein (CYP/P-gp) modulators, and large artery atherosclerotic disease (LAD).1

30 Jun 2023
thumb

Professor Leung Wai-Hong Thomas

Head of Division of Neurology
(Academic Affairs),
Lee Quo Wei Professor of Neurology
Assistant Dean (Education),
Faculty of Medicine,
The Chinese University of Hong Kong

thumb

Dr. Ip, Yiu-Ming Bonaventure

Assistant Professor,
Department of Medicine and Therapeutics,
The Chinese University of Hong Kong

Neurology. 2023.

Ip YMB, et al. Association of Alternative Anticoagulation Strategies and Outcomes in Patients With Ischemic Stroke While Taking a Direct Oral Anticoagulant.

Case review View All

Where clopidogrel fails: The struggle with CYP2C19 polymorphisms in the treatment of neurovascular diseases

03 Jan 2024